Skip to main content

Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing muscle biology therapeutics for debilitating diseases. The company develops small-molecule drug candidates targeting cardiac and skeletal muscle function, with lead compounds aimed at treating heart failure, hypertrophic cardiomyopathy, and amyotrophic lateral sclerosis. Revenue is primarily generated through strategic licensing agreements, research and development milestones, and royalty revenues from pharmaceutical development partners. Cytokinetics serves clinical research centers, cardiology specialists, neurology practices, and healthcare providers globally. The enterprise holds an established pioneer position in the scientific discovery of novel muscle activators and inhibitors within the global biopharmaceutical industry. Cytokinetics, Incorporated is headquartered in South San Francisco, California, United States, and its common stock is listed on the Nasdaq Global Select Market.

15 of the funds FundTelligence covers report a position in Cytokinetics.

Legal name
Cytokinetics Inc
Sector
Health Care
Country
United States
Funds holding it
15

Funds holding Cytokinetics

Showing the 8 largest of 15 funds holding it.

Loading...